Dicerna Pharmaceuticals, a Second Generation RNA Interference...

Dicerna Pharmaceuticals, Inc. , an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology , today announced a second closing of its Series A financing, receiving ...

Leave a Comment

Posted by: roboblogger

Full Story: BioSpace

Related Topix

Business - Financial Services, Venture Capital, Biotech, Emerging Technology, Alnylam Pharmaceuticals, Investment Services

Comments

Type in your comments to post to the forum

Name
(appears on your post)

Comments

Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Your town. Your news. Your take.

What is Topix?

Topix is the largest news community on the web.

We take news from over 60,000 sources and categorize those stories to over 40,600 locations and 450,000 topics.

Topix breaks the mold of traditional news sites by allowing our users to edit the news. We've built a suite of editing tools, so Topix users can make sure all the stories that matter get the attention they deserve.

The best part? You can comment on everything. Every story, every poll, every user-submitted photo.

Jump in, find a topic and start talking!

By the way, if you're interested in learning more about Topix, visit our blog.

Dicerna Pharmaceuticals, a Second Generation RNA Interference...

Daily Horoscope for October 6

Scorpio

Alnylam Pharmaceuticals News

Most Popular

Los Angeles Jobs